Market Trends of Global Guillain-Barre Syndrome Industry
This section covers the major market trends shaping the Guillain Barre Syndrome Market according to our research experts:
Intravenous Immunoglobulin Segment is Expected to Hold the Large Market Share Over the Forecast Period
Intravenous immunoglobulin (IVIG) therapy is the use of a mixture of antibodies (immunoglobulins) to treat health conditions, including primary immunodeficiency, immune thrombocytopenic purpura, chronic inflammatory demyelinating polyneuropathy, Kawasaki disease, certain cases of HIV/AIDS, measles, Guillain-Barré syndrome, and certain other infections. Depending on the formulation, it can be injected into the muscle, a vein, or under the skin.
Intravenous immunoglobulins are expected to account for a large share of the market, which can be attributed to the availability of a wide range of IVIG products such as Gamunex, Gammagard, and Privigen in the market and increased adoption of treatment by off-label use of intravenous immunoglobulins due to the rising prevalence of multifocal motor neuropathy, dermatomyositis, polymyositis, stiff person syndrome, and relapsing-remitting multiple sclerosis. Furthermore, according to the Centers for Disease Control and Prevention, June 2022 update, GBS affects about 3,000-6,000 people each year in the United States. Such a burden of disease is fueling the demand for effective treatment, which is expected to drive the growth of the market segment over the forecast period.
In addition, increasing research studies for intravenous immunoglobulin (IVIG) are also expected to boost the growth of the market segment. For instance, in November 2021, the study titled "Mini-pool Intravenous Immunoglobulin (MP-IVIG) in Guillain-Barré Syndrome" an interventional clinical trial by Assiut University is expected to be completed by December 2022. Such clinical studies may lead to the development of a newer products in the future and thus are expected to drive the growth of the market segment.
Thus, all the aforementioned factors are expected to boost segment growth over the forecast period.
North America Dominates the Market and Expected to do Same Over the Forecast Period.
North America is expected to dominate the overall GBS market throughout the forecast period. The dominance is due to several factors, such as the increasing geriatric population with higher chances of acquiring GBS, the presence of major market players, and growing awareness regarding GBS within the population.
According to the Centers for Disease Control and Prevention (CDC) article updated in June 2022, infection with Campylobacter jejuni, which causes diarrhea, is one of the most common causes of GBS. It also reported that people of any age group can develop GBS, but the risk of GBS increases in people aged over 50 years. Additionally, as per the Statistics Canada 2021 census, there were around 7,021,430 people aged 65 years or above, out of which 3,224,680 were males and 3,796,750 were females. Such an increase in the geriatric population coupled with the high risk of acquiring GBS is expected to boost the market's growth in the near future.
Moreover, the funding from public organizations for the different projects related to the GBS is expected to boost the growth of the market in North America. For instance, in October 2021, the National Institute of Neurological Disorders and Stroke (NINDS) approved USD 427,625 funding for co-investigators Brad Wright, Ph.D., Rebecca Traub, MD, and Chip Howard, MD for the project dealing with the understanding of Guillain-Barre syndrome using medicare claims and is expected to be completed by February 2023.
Thus, owing to the abovementioned factors, the studied market in the North American region is expected to boost the growth of the market.
